Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

-Duchenne:Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen -

-Duchenne:First participant enrolled in IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled, ex-U.S. clinical trial, with dosing expected in Q1 2026 -

-FA:First participant dosed in Phase 1b FALCON clinical trial; FDA Orphan Drug designation granted to SGT-212, the only dual route of administration gene therapy in development to treat Friedreich’s ataxia (FA)-

-CPVT:Clinical trial sites activated for ARTEMIS, a Phase 1b first-in-human clinical trial evaluating SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT); participant screening is underway-

-Capsids (AAV-SLB101):Executed 50+ agreements, including licenses, with corporations, institutions and academic labs for the use of proprietary, next-generation capsid AAV-SLB101 -

CHARLESTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will provide a corporate update outlining progress in advancing its neuromuscular and cardiac gene therapy programs in a presentation delivered by Bo Cumbo, President and CEO, at the 44thAnnual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT (8:15 p.m. ET).

“Over the past year, we have executed across our pipeline, building critical momentum as we enter 2026 with four active clinical trials in three devastating neuromuscular and cardiac rare diseases with significant unmet need, including the recently announced dosing of the first participant in our Phase 1b FALCON trial evaluating SGT-212 for the treatment of FA,” said Mr. Cumbo. “By rapidly and responsibly advancing innovative science and forging collaborations to enhance gene therapy delivery using our next-generation capsid, we are determined to build a better future for the patient communities we serve while driving value for our shareholders. With multiple regulatory interactions planned in the coming months, we aim to achieve alignment on a potential accelerated approval pathway for SGT-003 and to bring our investigational therapy to market to meet the overwhelming demand from the Duchenne community.”

Highlights from the presentation to be given at the J.P. Morgan Healthcare Conference include:

Ex-U.S.:

SGT-212 for Friedreich’s ataxia (FA)

Platform Technologies – CapsidsSolid continues to broaden access to its proprietary next-generation capsid, AAV-SLB101, designed with the goal of enhancing skeletal muscle and cardiac tropism with reduced biodistribution to the liver.

44thAnnual J.P. Morgan Healthcare Conference WebcastMr. Cumbo will present at the 44thAnnual J.P. Morgan Healthcare Conference today at 5:15 p.m. PT (8:15 p.m. ET). A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or byclicking here. A webcast replay will be archived for 30 days on the Events page.

About Solid BiosciencesSolid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic neuromuscular and cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visitwww.solidbio.com.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the company; the ability to successfully achieve and execute on the company’s goals, priorities and key clinical and preclinical milestones; strategies and expectations for the company’s SGT-003, SGT-212 and SGT-501 programs; expectations for additional site activations, planned enrollment, planned data announcements, planned regulatory interactions and the potential approval pathways for SGT-003; plans for data announcements for the clinical trial of SGT-212; timing of planned enrollment and data announcements for the clinical trial SGT-501; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “working” and similar expressions. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the company’s ability to advance SGT-003, SGT-212, SGT-501, SGT-601 and other preclinical programs, capsid libraries and other enabling technologies on the timelines expected or at all; obtain and maintain necessary approvals from the FDA and other regulatory authorities; replicate in clinical trials positive results found in preclinical studies and early-stage clinical trials of the company’s product candidates; obtain, maintain or protect intellectual property rights related to its product candidates; enroll patients in ongoing trials; activate clinical trial sites; replicate preliminary or interim data from clinicals trials in the final data of such trials; compete successfully with other companies that are seeking to develop Duchenne, FA, CPVT and other neuromuscular and cardiac treatments and gene therapies; manage expenses; and raise the substantial additional capital needed, on the timeline necessary, to continue development of SGT-003, SGT-212, SGT-501, SGT-601 and other candidates, achieve its other business objectives and continue as a going concern. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company’s views as of the date hereof and should not be relied upon as representing the company’s views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so.

Solid Biosciences Investor Contact:Nicole AndersonDirector, Investor Relations and Corporate CommunicationsSolid Biosciences Inc.investors@solidbio.com